Ann: Quarterly update and Appendix 4C, page-3

My bet is that Q1 FY23 is going to be higher or on par than Q1 FY22 given that we are experiencing a 3rd Omicron wave. Also I would imagine that clients that stocked up SARS-CoV-2 kits in Q3 FY22 likely didn't buy in Q4 FY22 (or with smaller orders), and they will hopefully be restocking and we could see some further increased sales in Q1 FY23. Also good to see that increasing contribution from sale of non-SARS-CoV-2 kits, as whilst it has been a great cash cow it will be good if they do not have to rely on that income... IMHO

@cambam Whilst cash outflows of 2.2m for Q4 FY22 there was substantial investments in equipment for placement at customer sites, so hopefully that will also provide meaningful revenue in the next Qtr. They also have enough cash to run at these levels for circa 4 years which gives a lot of runway to get Easyscreen approved by the FDA and generating sales without diluting shareholders... Hopefully the FDA approval process is faster than the recruitment and samples which took ages to finalise.

I topped up my position yesterday and still believe GSS can return decent gains to shareholders.

GLTAH